A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) versus Efavirenz (EFV) plus TDF and FTC in Antiretroviral-Naïve HIV-1/HCV Co-infected Subjects

Registry ID

EUCTR2005-001431-30

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Abbott GmbH & Co. KG

Start date

2005-06-22

Completion date

2013-07-05

Last update

2026-08-16

Conditions

• HIV-1 infection

Summary

To assess the safety, tolerability, and antiviral activity of two treatment strategies in HIV-1/HCV co-infected subjects: -LPV/r-based induction/maintenance strategy; -EFV-based three-drug regimen.

Locations

• , , UK
• , , Ireland

Related clinical trials

• Phase 3 Double-Blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® (Bictegravir/ Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People with HIV-1

View on source registry